Weekly Analysts’ Ratings Updates for HCA Healthcare (HCA)

A number of firms have modified their ratings and price targets on shares of HCA Healthcare (NYSE: HCA) recently:

• 3/4/2026 – HCA Healthcare had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 2/25/2026 – HCA Healthcare had its price target raised by Mizuho from $540.00 to $585.00. They now have an “outperform” rating on the stock.
• 2/23/2026 – HCA Healthcare had its price target raised by UBS Group AG from $598.00 to $635.00. They now have a “buy” rating on the stock.
• 2/20/2026 – HCA Healthcare had its price target raised by JPMorgan Chase & Co. from $420.00 to $535.00. They now have a “neutral” rating on the stock.
• 2/14/2026 – HCA Healthcare was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 2/9/2026 – HCA Healthcare was given a new $541.00 price target by Sanford C. Bernstein.
• 2/6/2026 – HCA Healthcare had its price target raised by Argus from $530.00 to $560.00. They now have a “buy” rating on the stock.
• 2/2/2026 – HCA Healthcare was given a new $540.00 price target by Mizuho.
• 1/30/2026 – HCA Healthcare had its price target raised by Wells Fargo & Company from $452.00 to $481.00. They now have an “equal weight” rating on the stock.
• 1/28/2026 – HCA Healthcare had its “buy” rating reaffirmed by TD Cowen.
• 1/28/2026 – HCA Healthcare was given a new $503.00 price target by KeyCorp.
• 1/28/2026 – HCA Healthcare had its “market perform” rating reaffirmed by Sanford C. Bernstein.
• 1/28/2026 – HCA Healthcare had its price target raised by UBS Group AG from $525.00 to $598.00. They now have a “buy” rating on the stock.
• 1/28/2026 – HCA Healthcare had its price target raised by Oppenheimer Holdings, Inc. from $500.00 to $540.00. They now have an “outperform” rating on the stock.
• 1/28/2026 – HCA Healthcare was given a new $588.00 price target by UBS Group AG.
• 1/28/2026 – HCA Healthcare had its price target raised by Cantor Fitzgerald from $525.00 to $588.00. They now have an “overweight” rating on the stock.
• 1/28/2026 – HCA Healthcare had its price target raised by KeyCorp from $500.00 to $550.00. They now have an “overweight” rating on the stock.
• 1/28/2026 – HCA Healthcare had its price target raised by Barclays PLC from $494.00 to $551.00. They now have an “overweight” rating on the stock.
• 1/28/2026 – HCA Healthcare had its price target raised by The Goldman Sachs Group, Inc. from $520.00 to $558.00. They now have a “buy” rating on the stock.
• 1/28/2026 – HCA Healthcare had its price target raised by Leerink Partners from $507.00 to $573.00. They now have an “outperform” rating on the stock.
• 1/28/2026 – HCA Healthcare had its price target raised by Jefferies Financial Group Inc. from $535.00 to $590.00. They now have a “buy” rating on the stock.
• 1/28/2026 – HCA Healthcare had its price target raised by Royal Bank Of Canada from $525.00 to $555.00. They now have an “outperform” rating on the stock.
• 1/28/2026 – HCA Healthcare had its price target raised by Deutsche Bank Aktiengesellschaft from $500.00 to $558.00. They now have a “buy” rating on the stock.
• 1/28/2026 – HCA Healthcare had its price target raised by Truist Financial Corporation from $520.00 to $546.00. They now have a “buy” rating on the stock.
• 1/22/2026 – HCA Healthcare had its “overweight” rating reaffirmed by KeyCorp. They now have a $500.00 price target on the stock.
• 1/22/2026 – HCA Healthcare had its price target raised by Jefferies Financial Group Inc. from $525.00 to $535.00. They now have a “buy” rating on the stock.
• 1/15/2026 – HCA Healthcare had its price target raised by Leerink Partners from $470.00 to $507.00. They now have an “outperform” rating on the stock.
• 1/7/2026 – HCA Healthcare had its price target raised by Wells Fargo & Company from $431.00 to $452.00. They now have an “equal weight” rating on the stock.
• 1/6/2026 – HCA Healthcare had its “market perform” rating reaffirmed by Sanford C. Bernstein. They now have a $503.00 price target on the stock.
• 1/5/2026 – HCA Healthcare had its price target raised by Truist Financial Corporation from $495.00 to $520.00. They now have a “buy” rating on the stock.

HCA Healthcare Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 17th will be given a $0.78 dividend. This is a boost from HCA Healthcare’s previous quarterly dividend of $0.72. This represents a $3.12 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Tuesday, March 17th. HCA Healthcare’s dividend payout ratio (DPR) is presently 10.15%.

Insider Activity at HCA Healthcare

In other news, SVP Christopher F. Wyatt sold 4,000 shares of the stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $505.00, for a total value of $2,020,000.00. Following the completion of the transaction, the senior vice president directly owned 44,379 shares in the company, valued at approximately $22,411,395. This represents a 8.27% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael R. Mcalevey sold 1,694 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $533.37, for a total transaction of $903,528.78. Following the sale, the executive vice president directly owned 8,853 shares of the company’s stock, valued at approximately $4,721,924.61. This trade represents a 16.06% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 15,214 shares of company stock valued at $7,797,595. 1.30% of the stock is currently owned by company insiders.

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.